Overview
Choroideremia is a rare, X-linked genetic disorder characterized by progressive degeneration of retinal structures, including the choroid, leading to vision loss and potential blindness 1.Diagnosis
Clinical history and family history of X-linked retinal degeneration
Fundus examination revealing atrophy of the choriocapillaris and retinal pigment epithelium
Electroretinography (ERG) showing reduced b-wave amplitudes
Genetic testing for CHM gene mutations 1Management
Gene Therapy: Subretinal administration of timrepigene emparvovec for adult males with choroideremia (high-dose 1.0 × 10^8 vg/eye) 1
Monitoring and supportive care including low vision aids and regular ophthalmologic follow-upsSpecial Populations
Pediatrics: Limited data; management typically focuses on supportive care and monitoring progression 1
Elderly: No specific considerations beyond standard management approaches 1
Comorbidities: No specific guidelines provided; manage based on individual patient needs 1Key Recommendations
Consider subretinal timrepigene emparvovec gene therapy for adult males with choroideremia to potentially halt disease progression (Evidence: Strong 1)
Regular monitoring with fundus examination and ERG is essential for assessing disease progression and treatment efficacy (Evidence: Moderate 1)
Implement supportive care measures including low vision aids tailored to individual needs (Evidence: Expert opinion 1)References
1 MacLaren RE, Fischer MD, Gow JA, Lam BL, Sankila EK, Girach A et al.. Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nature medicine 2023. link